secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0001193125-23-206255
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno completes enrollment in PWS Study C602; Q2 net loss $8.5M
----------------------------------------------------------------

- Completed enrollment in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome.
- Top-line data expected around end of Q3 2023; could support NDA submission to FDA.
- Received $10M from SPA warrant exercise; cash and equivalents $19.4M as of June 30, 2023.
- Net loss for Q2 2023 was $8.5M ($0.81 per share) vs $6.7M ($0.72 per share) in Q2 2022.
- R&D expenses $5.1M in Q2 2023, up from $3.7M year-over-year due to clinical progress.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312523206255/0001193125-23-206255-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312523206255/d452584d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-206255

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer